1. Home
  2. VGZ vs TLSI Comparison

VGZ vs TLSI Comparison

Compare VGZ & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Vista Gold Corp

VGZ

Vista Gold Corp

HOLD

Current Price

$1.68

Market Cap

316.8M

Sector

N/A

ML Signal

HOLD

Logo TriSalus Life Sciences Inc.

TLSI

TriSalus Life Sciences Inc.

HOLD

Current Price

$4.34

Market Cap

270.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VGZ
TLSI
Founded
1983
2010
Country
United States
United States
Employees
N/A
102
Industry
Medical Specialities
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
316.8M
270.2M
IPO Year
1996
N/A

Fundamental Metrics

Financial Performance
Metric
VGZ
TLSI
Price
$1.68
$4.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$3.75
$7.00
AVG Volume (30 Days)
3.0M
448.5K
Earning Date
05-12-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$35.45
Revenue Next Year
N/A
$37.58
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.91
$2.20
52 Week High
$3.13
$7.95

Technical Indicators

Market Signals
Indicator
VGZ
TLSI
Relative Strength Index (RSI) 40.79 54.99
Support Level $1.57 $4.27
Resistance Level $1.89 $4.38
Average True Range (ATR) 0.10 0.30
MACD -0.01 -0.01
Stochastic Oscillator 42.27 65.53

Price Performance

Historical Comparison
VGZ
TLSI

About VGZ Vista Gold Corp

Vista Gold Corp operates as a development-stage company in the gold mining industry. Its flagship asset is the Mt Todd Gold Project, a development-stage gold deposit located in the Tier-1 jurisdiction of Northern Territory, Australia. Mt Todd offers a large gold mineral reserve, development optionality, expansion opportunities, exploration upside, local infrastructure, community support, and demonstrated economic feasibility. It operates in one reportable segment, consisting of acquisition, exploration and evaluation activities which are focused on Australia.

About TLSI TriSalus Life Sciences Inc.

TriSalus Life Sciences Inc is an oncology-focused medical technology business integrating its delivery technology with standard-of-care therapies and its investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 (TRL9) agonist, for patients with solid tumors. The company developed Pressure-Enabled Drug Delivery (PEDD) to overcome high intratumoral pressure and off-target delivery. Its 510(k) cleared device, the TriNav Infusion System using PEDD technology, is used for interventional radiology procedures including transarterial radioembolization (TARE) and transarterial chemoembolization (TACE) in patients with primary liver cancer or liver metastases. It has one reportable segment and generates revenue from sales of PEDD infusion systems, principally related to TriNav.

Share on Social Networks: